WO2023235666A3 - Human antibodies to bordetella pertussis and uses therefor - Google Patents

Human antibodies to bordetella pertussis and uses therefor Download PDF

Info

Publication number
WO2023235666A3
WO2023235666A3 PCT/US2023/067387 US2023067387W WO2023235666A3 WO 2023235666 A3 WO2023235666 A3 WO 2023235666A3 US 2023067387 W US2023067387 W US 2023067387W WO 2023235666 A3 WO2023235666 A3 WO 2023235666A3
Authority
WO
WIPO (PCT)
Prior art keywords
bordetella pertussis
human antibodies
uses therefor
therefor
bordetella
Prior art date
Application number
PCT/US2023/067387
Other languages
French (fr)
Other versions
WO2023235666A2 (en
Inventor
James E. CROWE
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of WO2023235666A2 publication Critical patent/WO2023235666A2/en
Publication of WO2023235666A3 publication Critical patent/WO2023235666A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/235—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Bordetella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure is directed to antibodies binding to Bordetella pertussis toxin and methods for use therefor.
PCT/US2023/067387 2022-05-31 2023-05-24 Human antibodies to bordetella pertussis and uses therefor WO2023235666A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263347175P 2022-05-31 2022-05-31
US63/347,175 2022-05-31

Publications (2)

Publication Number Publication Date
WO2023235666A2 WO2023235666A2 (en) 2023-12-07
WO2023235666A3 true WO2023235666A3 (en) 2024-01-11

Family

ID=89025642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/067387 WO2023235666A2 (en) 2022-05-31 2023-05-24 Human antibodies to bordetella pertussis and uses therefor

Country Status (1)

Country Link
WO (1) WO2023235666A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150902A1 (en) * 2008-04-11 2010-06-17 Jean-Francois Haeuw Anti-cd151 antibodies and their use in the treatment of cancer
US20180256699A1 (en) * 2014-12-08 2018-09-13 Board Of Regents, The University Of Texas System Bordetella adenylate cyclase toxin vaccines and neutralizing antibodies
US20190367616A1 (en) * 2016-11-18 2019-12-05 Symphogen A/S Anti-PD-1 Antibodies and Compositions
WO2020223573A2 (en) * 2019-04-30 2020-11-05 Gigagen, Inc. Recombinant polyclonal proteins and methods of use thereof
US20210214420A1 (en) * 2018-06-18 2021-07-15 Dxdiscovery Inc. Methods and compositions for pertussis diagnosis
CN114106171A (en) * 2020-12-21 2022-03-01 天士力生物医药股份有限公司 anti-AQP 4 antibodies and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150902A1 (en) * 2008-04-11 2010-06-17 Jean-Francois Haeuw Anti-cd151 antibodies and their use in the treatment of cancer
US20180256699A1 (en) * 2014-12-08 2018-09-13 Board Of Regents, The University Of Texas System Bordetella adenylate cyclase toxin vaccines and neutralizing antibodies
US20190367616A1 (en) * 2016-11-18 2019-12-05 Symphogen A/S Anti-PD-1 Antibodies and Compositions
US20210214420A1 (en) * 2018-06-18 2021-07-15 Dxdiscovery Inc. Methods and compositions for pertussis diagnosis
WO2020223573A2 (en) * 2019-04-30 2020-11-05 Gigagen, Inc. Recombinant polyclonal proteins and methods of use thereof
CN114106171A (en) * 2020-12-21 2022-03-01 天士力生物医药股份有限公司 anti-AQP 4 antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROTKB ANONYMOUS : "A0A0R3KTY0 · A0A0R3KTY0_9BRAD", XP093128306, retrieved from UNIPROT *

Also Published As

Publication number Publication date
WO2023235666A2 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
CR20220545A (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
NZ568769A (en) Human monoclonal antibodies against CD20
WO2022031940A3 (en) Il28ra binding molecules and methods of use
MX2020009313A (en) Compositions and methods for skin renewal.
BG108499A (en) A novel engineered superantigen for human therapy
MX2022000325A (en) Dll3-targeting antibodies and uses thereof.
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2018006372A (en) Anti-5t4 antibodies and antibody-drug conjugates.
MX2018013525A (en) Dna antibody constructs for use against pseudomonas aeruginosa.
MX2022014995A (en) Methods of treating iga nephropathy with an april binding antibody.
WO2023178289A3 (en) Camptothecin conjugates
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
MX2023008000A (en) B7h4-targeted antibody-drug conjugates and methods of use thereof.
WO2023235666A3 (en) Human antibodies to bordetella pertussis and uses therefor
WO2022204713A3 (en) Antibodies to sars-cov-2
WO2021195385A8 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
WO2021187995A3 (en) The method of obtaining saplings of the common ash (fraxinius excelsior l.) and the media suitable for use in this method
MX2022016322A (en) High affinity antibodies targeting tau phosphorylated at serine 413.
MX2022005157A (en) Harnessing the power of microbiota and metabolites for the treatment of cancer.
MX2022004270A (en) Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency.
WO2023031623A3 (en) Synthesis of bicycle toxin conjugates, and intermediates thereof
WO2022246053A3 (en) Immune checkpoint multivalent particles compositions and methods of use
WO2021216667A3 (en) Antibodies to chitinase 3-like-1 and methods of use therefor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23816850

Country of ref document: EP

Kind code of ref document: A2